Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sangoma Technologies Corporation (SANG : NSDQ)
 
 • Company Description   
Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a genomic medicines pipeline. Sangamo Therapeutics is based in BRISBANE, Calif.

Number of Employees: 570

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.06 Daily Weekly Monthly
20 Day Moving Average: 985 shares
Shares Outstanding: 20.57 (millions)
Market Capitalization: $165.76 (millions)
Beta:
52 Week High: $25.55
52 Week Low: $8.05
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -40.03% -34.34%
12 Week -35.42% -27.42%
Year To Date -52.21% -41.62%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 Renfrew Drive Suite 100
-
MARKHAM,A6 L3R 9R6
CAN
ph: 800-388-2475
fax: -
investorrelations@sangoma.com http://www.sangoma.com
 
 • General Corporate Information   
Officers
William Wignall - Chief Executive Officer and President
Norman A. Worthington - Chairman
David Moore - Chief Financial Officer
Marc Lederman - Director
Allan Brett - Director

Peer Information
Sangoma Technologies Corporation (CORR.)
Sangoma Technologies Corporation (RSPI)
Sangoma Technologies Corporation (CGXP)
Sangoma Technologies Corporation (BGEN)
Sangoma Technologies Corporation (GTBP)
Sangoma Technologies Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 80100R408
SIC: 6770
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 10/05/22
Share - Related Items
Shares Outstanding: 20.57
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $165.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.42
Price/Cash Flow: -
Price / Sales: 0.78
EPS Growth
vs. Year Ago Period: -2,200.00%
vs. Previous Quarter: -162.50%
Sales Growth
vs. Year Ago Period: 96.98%
vs. Previous Quarter: 1.63%
ROE
03/31/22 - -4.48
12/31/21 - -2.26
09/30/21 - -1.40
ROA
03/31/22 - -3.05
12/31/21 - -1.56
09/30/21 - -0.95
Current Ratio
03/31/22 - 0.70
12/31/21 - 0.97
09/30/21 - -
Quick Ratio
03/31/22 - 0.50
12/31/21 - 0.78
09/30/21 - -
Operating Margin
03/31/22 - -7.97
12/31/21 - -4.47
09/30/21 - -2.47
Net Margin
03/31/22 - -6.04
12/31/21 - -4.29
09/30/21 - -2.26
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 19.06
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.26
12/31/21 - 0.19
09/30/21 - -
Debt-to-Capital
03/31/22 - 20.45
12/31/21 - 16.11
09/30/21 - -
 

Powered by Zacks Investment Research ©